Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
天境生物科技(上海)有限公司 IMab
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
2024-04-05 19:00
I-Mab Announces Closing of the Divestiture of Business Operations in China
2024-04-03 04:01
I-Mab Reports Full Year 2023 Financial Results and Business Update
2024-03-15 05:00
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
2024-02-07 19:00
I-Mab Announces Participation at Jefferies and Piper Conferences in November
2023-11-06 21:00
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
2023-11-02 20:00
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
2023-11-01 20:00
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
2023-10-16 20:00
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
2023-10-10 20:00
I-Mab Announces Upcoming Participation at September Conferences
2023-09-05 20:00
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
2023-08-17 18:00
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
2023-08-08 20:00
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
2023-07-05 20:00
I-Mab Announces the Appointment of Raj Kannan as CEO
2023-06-22 20:00
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
2023-05-26 05:01
I-MAB Filed 2022 Annual Report on Form 20-F
2023-05-01 20:00
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
2023-04-26 21:16
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
2023-04-25 13:46
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
2023-04-24 21:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
2023-03-31 18:30
1
2
3
4
5
8